TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06058949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Protection and Promotion
Description: An adaptive integrated Total Worker Health® program. Virtual 8-week program that's been contextualized to the physical and mental health needs of sign language interpreters. It will examine biomechanics, sleep hygiene, vicarious trauma and burnout, demand-control schema, physical activity, emotional management strategies, proper nutrition and examination of worksite.
Study: NCT06288373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab paclitaxel: 260 mg/m2，D1，q3w （3 cycles），intravenous infusion, administered over 30min.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical surgery
Description: Radical surgery
Study: NCT06058949

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health Program
Description: Virtual 8-week program that addresses participant sleep hygiene, physical activity and proper nutrition.
Study: NCT04772079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching deucravacitinib
Description: Specified dose on specified days
Study: NCT05591118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulant Therapy
Description: All subjects will receive anticoagulation for a minimum of 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulant Therapy
Description: All subjects will receive anticoagulation for a minimum of 3 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheter-Directed Therapy
Description: The endovascular physician can choose to use either mechanical thrombectomy (MT) using a device cleared by the FDA to treat PE or catheter-directed thrombolysis (CDL) using an infusion catheter cleared by the FDA to administer thrombolytic drugs for the treatment of PE
Study: NCT05571449

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open reduction and internal fixation
Description: Internal fixation of the fracture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation
Description: Internal fixation of the fracture

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard osteosynthesis planning
Description: Plain radiograph and CT images are used

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard osteosynthesis planning
Description: Plain radiograph and CT images are used

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3-D model osteosynthesis planning
Description: A 3D plastic model made from CT images is used
Study: NCT04972565

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care plus Inspiratory Muscle Training (IMT)
Description: Participants will receive usual care and will also be provided with a personalized prescription for an IMT program for 8 weeks. Participants will perform two daily IMT sessions of 30 breaths (\< 5 minutes/session), 5 days per week in their home environment. IMT intensity will be progressed weekly by 5-10% of the baseline maximal inspiratory pressure if the Borg Dyspnea score is \< 7.
Study: NCT05572437

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Patients randomized to the treatment with music group (classical music), after assessment of anxiety using the APAIS scale, will be given headphones and classical music will be played from their stay in the pre-anesthesia room, during surgery and in the PACU.
Study: NCT05706909

Intervention type: DEVICE
Intervention: Genex with ABMC
Description: Core decompression, injection of autologous bone marrow concentrate and the use of genex® Bone graft Substitute as an adjunct associated with the decompression procedure
Study: NCT06066047

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TOUCH ATTENTIVE TREATMENT
Description: 15-minute treatment using constant touch (0.20 N, approx. 20 grams) developed after training with visual feedback.~* 5 minutes bilateral touch on external malleolus~* 5 minutes longitudinal occipital front grip for reciprocal tension membrane movement and Sutherland's fulcrum~* 5 minutes bilateral touch on acromion, for midline, centring diaphragms~Throughout the treatment, the practitioner maintained a focused attention on touch by voluntarily and constantly directing attention to the sensation/perception of the hands, perceiving texture, density, temperature, reactivity and motility of the tissue.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: AUDITORY ATTENTIVE TREATMENT
Description: 15-minute treatment using constant touch (0.20 N, approx. 20 grams) developed after training with visual feedback.~* 5 minutes bilateral touch on external malleolus~* 5 minutes longitudinal occipital front grip for reciprocal tension membrane movement and Sutherland's fulcrum~* 5 minutes bilateral touch on acromion, for midline, centring diaphragms~During the treatment, the operator's attention was focused on acoustic signals delivered through earphones. The beeps were delivered at random intervals between 0.5 and 2.0 seconds. The operator had to count the number of acoustic signals produced during the treatment period.
Study: NCT04207437

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration therapy
Description: vibration therapy using hand held vibration device
Study: NCT05080894

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Embodiment of a healthy virtual body in virtual reality and action observation/motor imagery of the subject's virtual body performing high-level lower limb exercises.
Study: NCT05437848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Cotadutide
Description: Cotadutide: subcutaneous (SC) injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection
Study: NCT05027503

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise with hippotherapy simulator
Description: 30-minute (5 min warm-up+20 min exercise+5 min cool-down) center-based exercise with the hippotherapy simulator will be done 2 days a week for 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory Physiotherapy
Description: Respiratory physiotherapy includes breathing control (5x2), diaphragmatic breathing exercises (5x2), thoracic expansion exercises (5x2), incentive spirometer (5x2), opep device (5x2), postural drainage and percussion and cough improvement techniques (10 min). Home-based respiratory physiotherapy will be applied twice a day and every day of the week for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory Physiotherapy
Description: Respiratory physiotherapy includes breathing control (5x2), diaphragmatic breathing exercises (5x2), thoracic expansion exercises (5x2), incentive spirometer (5x2), opep device (5x2), postural drainage and percussion and cough improvement techniques (10 min). Home-based respiratory physiotherapy will be applied twice a day and every day of the week for 8 weeks.
Study: NCT05474079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise training
Description: The exercise training program will consist of individually tailored, progressive moderate-intensity aerobic exercise. Exercise training will comprise of a combination of treadmill, cross-trainer and cycle ergometer-based exercise. Exercise will progressively increase in both intensity and duration throughout the course of the intervention. Participants will begin the intervention with 30 minutes of moderate-intensity aerobic exercise at 40% HRR three times per week for the initial 4 weeks. From week 4, exercise intensity will increase to 50% HRR, and at week 6 the duration of each session will increase to 45 minutes. From week 8, participants will exercise at an intensity of 60% HRR for 45 minutes, and from week 10, this will increase to five sessions per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise training
Description: The exercise training program will consist of individually tailored, progressive moderate-intensity aerobic exercise. Exercise training will comprise of a combination of treadmill, cross-trainer and cycle ergometer-based exercise. Exercise will progressively increase in both intensity and duration throughout the course of the intervention. Participants will begin the intervention with 30 minutes of moderate-intensity aerobic exercise at 40% HRR three times per week for the initial 4 weeks. From week 4, exercise intensity will increase to 50% HRR, and at week 6 the duration of each session will increase to 45 minutes. From week 8, participants will exercise at an intensity of 60% HRR for 45 minutes, and from week 10, this will increase to five sessions per week.
Study: NCT05429814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menthol Application
Description: During the study, the patients' routine pharmacological treatments will continue and menthol will be applied only to reduce the effect of neuropathy. In the study, menthol 1% will be used topically, as it was used in studies after the literature review. Although it was stated in the studies that menthol had no side effects, it was decided to mix menthol with water-based cream according to the literature recommendation. Researchers will first determine how many grams of menthol will be sufficient by applying menthol to their hands and feet.After the gram of the prepared mixture is determined, it will be given to the patients. Patients in the intervention group will be taught how to regularly apply menthol cream (topical menthol) to their hands and feet, twice a day, every day. The effect on CIPN will be evaluated in patients with CIPN for 3 weeks immediately before and after 6 weeks of treatment with menthol administration.
Study: NCT06312306

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Anodal tDCS applied using a direct current stimulator and two saline-soaked electrodes. The anode electrodes will be positioned approximately 2 cm anterior to Cz according to the International 10/20 EEG System. The cathode will be positioned over the inion. Stimulation intensity will be at 2.0 milliampere (as suggested to achieve excitation in the lower limb motor cortex areas)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates based core training
Description: The Pilates training program will last 30 min per session, Each action in the training will be repeated eight times these actions are at beginner level, considering the characteristics of stroke patients. The selected exercises will be given to all patients and progressed week-wise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physiotherapy program
Description: Conventional physiotherapy program:~* Stretching Slow sustained stretching of spastic muscles (generally hip flexors and adductors, knee extensors or flexors and ankle plantar flexors)~* Strengthening Abdominals, lumbar spine extensors, hip flexors, extensors and abductors, knee extensors and flexors and ankle dorsi flexors~* Gait training In level surface and in stairs

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy program
Description: Conventional physiotherapy program:~* Stretching Slow sustained stretching of spastic muscles (generally hip flexors and adductors, knee extensors or flexors and ankle plantar flexors)~* Strengthening Abdominals, lumbar spine extensors, hip flexors, extensors and abductors, knee extensors and flexors and ankle dorsi flexors~* Gait training In level surface and in stairs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physiotherapy program
Description: Conventional physiotherapy program:~* Stretching Slow sustained stretching of spastic muscles (generally hip flexors and adductors, knee extensors or flexors and ankle plantar flexors)~* Strengthening Abdominals, lumbar spine extensors, hip flexors, extensors and abductors, knee extensors and flexors and ankle dorsi flexors~* Gait training In level surface and in stairs
Study: NCT02384720

Intervention type: OTHER
Intervention: Age: 20-40years
Study: NCT06288373

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: external beam radiation therapy (EBRT) + brachytherapy
Description: Radiation therapy per standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Chemotherapy administered concurrent with radiation therapy，cisplatin 40 mg/m2 IV once per week (QW) for 5 weeks
Study: NCT05016947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet, taken by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Intravenous infusion
Study: NCT06398106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proactive TDM-based dosing of secukinumab
Description: Maintenance/normal dose is 300 mg/4 weeks.~First dose reduction step: 300 mg/6 weeks. Second dose reduction step: 300 mg/8 weeks. Further dose reduction steps: prolongation with 1 additional week~First dose escalation step: 300 mg/3 weeks Second dose escalation step: 300 mg/2 weeks Further dose escalation step: shortening with 1 additional week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proactive TDM-based dosing of ixekizumab
Description: Maintenance/normal dose is 80 mg/4 weeks.~First dose reduction step: 80 mg/6 weeks. Second dose reduction step: 80 mg/8 weeks Further dose reduction steps: prolongation with 1 additional week~First dose escalation step: 80 mg/3 weeks Second dose escalation step: 80 mg/2 weeks Further dose escalation step: shortening with 1 additional week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proactive TDM-based dosing of guselkumab
Description: Maintenance/normal dose is 100 mg/8 weeks.~First dose reduction step: 100 mg/12 weeks. Second dose reduction step: 100 mg/16 weeks. Further dose reduction steps: prolongation with 1 additional week~First dose escalation step: 100 mg/6 weeks Second dose escalation step: 100 mg/4 weeks Further dose escalation step: shortening with 1 additional week
Study: NCT04715451

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel Swaddle
Description: A novel swaddling method.
Study: NCT05446168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tributyrin
Description: Post-biotic short chain fatty acid dietary supplement. Participants will take 500mg TID tributyrin supplement for 30 days +/- 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tributyrin
Description: Post-biotic short chain fatty acid dietary supplement. Participants will take 500mg TID tributyrin supplement for 30 days +/- 7 days.
Study: NCT06096779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a dose of 1200 mg by IV infusion on Day 1 of each 21-day cycle.
Study: NCT05235295

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided sacroiliac joint injection
Description: Using ultrasound the sacral hiatus in transverse position was identified. Then, sliding laterally and cephalad in transverse position, the posterior superior iliac spine and the posterior sacroiliac joint were identified. The needle was advanced toward the posterior joint space from medial to lateral, using an in-plane technique.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flouroscopy-guided sacroiliac joint injection
Description: Using anterior posterior and contralateral oblique view the posterior joint line and inferior joint margin were identified and a needle was advanced at the point the posterior inferior joint line was most clearly seen.
Study: NCT02384720

Intervention type: OTHER
Intervention: Age: 41-64years

Intervention type: OTHER
Intervention: Age: ≥65years
Study: NCT06203808

Intervention type: OTHER
Intervention: COMPLETION OF QUESTIONNAIRES
Description: Both groups of patients will complete quality of life questionnaires at the time of treatment information, at 3 months, 6 months and at 12 months.

Intervention type: OTHER
Intervention: COMPLETION OF QUESTIONNAIRES
Description: Both groups of patients will complete quality of life questionnaires at the time of treatment information, at 3 months, 6 months and at 12 months.
Study: NCT05000320

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuronal Injury Panel
Description: A panel of neuronal and astroglial assays that may be a marker of brain injury.
Study: NCT05893290

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Exercise Group
Description: Therapeutic exercise sessions will begin with a short educational talk that provides information on proper body mechanics, and the benefits of exercise, followed by simple warm-ups and three different stretching and five different strengthening exercises that emphasize hip, abdominal, and back muscles. The frequency of repetitions of each stretching and strength exercise will be 10 with a holding time of 10 sec. Each set of strengthening exercises will be followed by a different set of stretching exercises. Sessions will end with a short unguided period of deep slow breathing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise+Basic Body Awareness Therapy Group
Description: This group will receive BBAT as well as therapeutic exercises. Therapeutic exercises will include strengthening, stretching, and stabilization exercises. BBAT will include postural alignment, breathing, and cognitive exercises.
Study: NCT06470724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structural visual approach
Description: The intervention comprised seven behavior approaches in this research defined as follows:~A successive approach: An approach to familiarization with the unfamiliar environment of the simulated dental office.~Tell-Feel-Show-Do (T-F-S-D): A dental approach explained to the patient's treatment by telling the patient what would happen, what he felt or did, and what had been done.~Visual pedagogy: Introduced dentistry to autistic children through visual media, such as pictures and photographs.~Audiovisual modeling: A learning process through audiovisual media, such as video and animation.~In-vivo modeling: Learning new activities by watching them in front of the model.~Behavioral trials: A learning strategy conducted through practicing the recent activity by him/herself.~Auto-modeling: A learning process following the activity of editing pictures during the prior visit of the patient.
Study: NCT06096779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a dose of 1200 mg by IV infusion on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1 of each 21-day cycle.
Study: NCT06557122

Intervention type: DEVICE
Group type: OTHER
Intervention: SOC and Advanced Bioengineered Skin Substitute
Description: SOC primary dressing with Helicoll®

Intervention type: OTHER
Group type: OTHER
Intervention: SOC and Active Comparator
Description: SOC primary dressing with Epifix® or Grafix®
Study: NCT05592158

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Socket preservation
Description: After tooth extraction, the socket will be filled with a collagen plug and covered with an amnion-chorion membrane.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Socket preservation
Description: After tooth extraction, the socket will be filled with a collagen plug and covered with an amnion-chorion membrane.
Study: NCT05257993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JPI-547
Description: * Subjects are administered this investigational product once a week for 5 days, and have wash-out period for 2 days (5 Days on-2 Days off).~* The investigational product is administered orally in a fasting state for 2 hours before and after meals at the same time (e.g., a certain time in the morning).~* Capsules should be swallowed whole and should not be chewed, crushed or split.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JPI-547
Description: * Subjects are administered this investigational product once a week for 5 days, and have wash-out period for 2 days (5 Days on-2 Days off).~* The investigational product is administered orally in a fasting state for 2 hours before and after meals at the same time (e.g., a certain time in the morning).~* Capsules should be swallowed whole and should not be chewed, crushed or split.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modified FOLFIRINOX
Description: * After IV administration of Oxaliplatin 65 mg/m2 for 2 hours~* After IV administration of Leucovorin 400 mg/m2 for 2 hours + IV administration of Irinotecan 135 mg/m2 for 90 minutes (Irinotecan is started 30 minutes after the start of Leucovorin administration and administered simultaneously during the last 90 minutes of Leucovorin administration, but administered separately using a Y-connector without mixing)~* Continuous IV infusion of 5-FU 2400 mg/m2 for 46 hours~* Repeated administration every 2 weeks on a 14-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine-nab-paclitaxel
Description: * After IV administration of nab-paclitaxel 100 mg/m2 for 30 minutes~* IV administration of Gemcitabine 1000 mg/m2 for 30 minutes~* Administration on Days 1, 8, and 15 on a 28-day cycle
Study: NCT05325645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712FUM/ Brexpiprazole fumarate
Description: 2 brexpiprazole QW tablets 24 mg (48 mg/dose) will be orally administered once weekly for 7weeks.(As an initial dose, one brexpiprazole QW tablet 24 mg and one placebo tablet will be orally administered (24 mg/dose))

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo tablets will be orally administered once weekly for 7weeks.